Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Recently, a new clinical presentation called "long covid" has been reported, for patients
with symptoms lasting for more than 4 weeks from the onset of the disease. Typically, the
symptoms comprise dyspnea, cough, headache, arthralgia, fever, abdominal pain, asthenia and
skin manifestations This project aims to evaluate the efficacy of Montelukast in improving
the quality of life associated with respiratory symptoms in patients with persistent COVID-19
symptoms. The main objective is to compare the efficacy of low-dose Montelukast versus
placebo to improve respiratory symptoms in patients with persistent COVID-19 symptoms.